Aimmune wins over ICER for peanut allergy product

PM Live

12 June 2019 - Analysts predict blockbuster status for first-in-class.

Aimmune is still a few months away from a potential US approval of its peanut allergy drug AR-101, but already has a thumbs up from the Institute for Clinical and Economic Review (ICER) on cost-effectiveness.

It’s an enviable position for a biotech striving to bring its first therapy to market, with ICER’s analysis concluding that the oral immunotherapy should fall well below its traditional threshold of $100,000-$150,000 per quality-adjusted life year (QALY).

Aimmune says ICER has concluded AR-101 is actually more cost-effective than simply avoiding peanuts when the broader societal costs of allergic reactions such as the effects on parents and caregivers are factored in.

Read PM Live article

Michael Wonder

Posted by:

Michael Wonder